See this earlier post:
↪ Paricalcitol plus chemotherapy raised partial response to 42% vs 9% in pancreatic cancer
#vitamindHD #paracalcitolHD #pancreaticcancerHD #cancerHD #danafarberHD
Louis points to a Nature Cancer study from Dana-Farber in which the vitamin D analog paricalcitol was combined with chemotherapy in 36 patients with untreated metastatic pancreatic cancer. Biopsies showed reduced fibroblast activation and more T-cell infiltration; the trial was not designed to prove survival benefit and it is not about vitamin D supplements.
See this earlier post:
↪ Paricalcitol plus chemotherapy raised partial response to 42% vs 9% in pancreatic cancer
#vitamindHD #paracalcitolHD #pancreaticcancerHD #cancerHD #danafarberHD
A vitamin D-based drug may have found a way to weaken pancreatic cancer’s hidden shield.
For years, one reason pancreatic cancer has been so hard to treat is that tumors build a dense, fibrotic barrier around themselves packed with activated fibroblasts that can block drugs and suppress immune attack.
But a new Nature Cancer study led by Dana-Farber and built on Salk Institute research suggests that paricalcitol, a prescription vitamin D analog, may help remodel that protective tumor environment.
In a small clinical trial of 36 patients with untreated metastatic pancreatic cancer, paricalcitol was safely combined with standard chemotherapy. Tumor biopsies showed reduced fibroblast activation and increased T-cell infiltration signs that the tumor’s defenses may have become more vulnerable.
The trial was not designed to prove survival benefit, but early signals were intriguing: patients receiving paricalcitol had higher response rates, and those with high vitamin D receptor expression appeared to do best.
This is not “take vitamin D for cancer.” It is a targeted drug strategy and it may be pointing toward a new way to make one of medicine’s deadliest cancers more treatable.
Would you want your tumor tested for vitamin D receptor levels if it could help guide treatment?
Source: Perez KJ, Dias Costa A, Jordan A, et al. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Nature Cancer. 2026; published May 25.